A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib

A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib

Lenvatinib is an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, as well as platelet-derived growth factor receptor α, RET, and KIT. At present, lenvatinib is used in the treatment of thyroid cancer and renal...

Full description

Bibliographic Details
Main Authors: Reiko Kimura-Tsuchiya, Eisaku Sasaki, Izumi Nakamura, Satoshi Suzuki, Satoshi Kawana, Chiyo Okouchi, Toshihiko Fukushima, Yuko Hashimoto, Shinichi Suzuki, Shigehira Saji
Format: Article
Language:English
Published: Karger Publishers 2018-02-01
Series:Case Reports in Oncology
Subjects:
Carcinoma of unknown primary
Lenvatinib
Squamous cell carcinoma
Online Access:https://www.karger.com/Article/FullText/486569

Internet

https://www.karger.com/Article/FullText/486569

Similar Items